Krystal Biotech ($NASDAQ:KRYS), Inc. is an innovative biotechnology company focused on developing and commercializing gene therapies to treat patients with serious skin conditions. The company’s second quarter earnings report has been met with enthusiasm from investors, as Krystal Biotech beat the consensus estimate of earnings-per-share (EPS) by $0.02, coming in at $-1.25.
In addition, revenue for the quarter was reported to be $2.04 billion, which was in line with expectations. This news was welcomed by investors, who were pleased to see that Krystal Biotech’s revenue did not suffer despite the coronavirus pandemic. Furthermore, Krystal Biotech’s technology and approach are gaining traction, as evidenced by the strong EPS result. The company is looking to expand its product pipeline, with several promising therapies in various stages of development. Looking ahead, Krystal Biotech is optimistic about its potential to develop groundbreaking gene therapies and to continue to deliver strong financial performance. Investors will be closely monitoring the company’s progress in the coming quarters, as they look for signs that it can remain competitive in a rapidly growing biopharmaceutical industry.
KRYSTAL BIOTECH released their earning report for FY2023 Q2 ending June 30 2021, showing a total revenue of 0.0M USD and a net loss of 16.36M USD. This was in line with analysts’ expectations, although the earnings beat estimates by $0.02. Looking at the figures from the last 3 years, total revenue has increased from 0.0M USD to 0.0M USD, a sign that KRYSTAL BIOTECH is progressing steadily. Despite the loss in net income for this quarter, KRYSTAL BIOTECH’s overall growth is positive and they remain a well-respected company in the biotech sector.
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Krystal Biotech. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Krystal Biotech. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Krystal Biotech. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Krystal Biotech are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Revenue was in line with expectations, and the stock opened at $109.1 and closed at $115.9, rising 6.8% from prior closing price of 108.5. This marks a significant increase for the company, which is likely to have a positive effect on investor confidence moving forward. Looking ahead, analysts are projecting further growth for KRYSTAL BIOTECH as the company continues to innovate and expand its products and services. Live Quote…
Analysis – Krystal Biotech Intrinsic Value Calculation
At GoodWhale, we provide deep financial analysis of public companies, including KRYSTAL BIOTECH. We have evaluated KRYSTAL BIOTECH’s financials and determined its fair value to be around $79.7, using our proprietary Valuation Line. Currently, the KRYSTAL BIOTECH stock is traded at $115.9, which is overvalued by 45.4%. This means that investors may be overestimating the company’s prospects and that the stock may not be a good buy at this time. More…
Risk Rating Analysis
Star Chart Analysis
The company is among several biopharmaceutical companies in the industry, including GT Biopharma Inc, Jounce Therapeutics Inc, and CytomX Therapeutics Inc, that are focused on developing innovative treatments for serious diseases.
GBT Biopharma Inc is a biopharmaceutical company that develops and commercializes treatments for cancer and other diseases. The company has a market cap of 35.49M as of 2022, which is relatively low compared to the market cap of many larger biopharmaceutical companies. Additionally, the company has a negative Return on Equity (ROE) of -132.59%, which indicates that the company is not able to generate profits from its investments and is likely not a good investment option.
– Jounce Therapeutics Inc ($NASDAQ:JNCE)
Jounce Therapeutics Inc is a biopharmaceutical company focused on developing therapies to improve the lives of people with cancer. The company currently has a market cap of 40.84M, making it relatively small when compared to other biotechnology companies in the sector. In terms of Return on Equity, Jounce Therapeutics Inc has a negative ROE of -57.85%. This reflects the company’s inability to generate profits and its need for additional capital to finance its operations. Despite these challenges, the company remains committed to its mission of developing innovative treatments for cancer patients.
– CytomX Therapeutics Inc ($NASDAQ:CTMX)
CytomX Therapeutics Inc is a biopharmaceutical company that develops innovative therapeutics for oncology and other diseases. The company’s market cap as of 2022 is 102.43M, indicating that the company has a moderate amount of liquidity and is in a good position to invest in its operations. However, its Return on Equity (ROE) of -160.27% suggests that the company has not been able to generate profits from its investments and is struggling to achieve positive earnings. This could be due to the high cost of research and development, or a lack of focus on core business activities.
Krystal Biotech reported impressive second quarter earnings, beating analyst estimates by a margin of $0.02. Revenue for the period remained in line with expectations, and was slightly up year over year. The news was greeted positively by investors, and the stock price responded in kind, moving up on the same day.
Looking ahead, analysts remain optimistic about the company’s outlook, and anticipate that Krystal Biotech will continue to leverage its strong product pipeline and rapid growth trajectory. With a focus on delivering long-term value to shareholders, it is expected that the stock will continue to show positive performance in the near future.